Corgenix
Broomfield, Colorado, United States
About Corgenix
Corgenix Medical Corporation is engaged in the research, development, manufacture, and marketing of in vitro diagnostic (IVD) products for use in disease detection and diagnosis in North America and internationally. It provides ELISA tests; vascular disease products, such as antiphospholipid antibody testing products; and products that are used in the diagnosis of bleeding and clotting disorders, including von Willebrand’s disease (hemophilia B). The company also provides the AspirinWorks test kit, a urine test that measures aspirin dosage; and liver disease products. In addition, it offers contract manufacturing services to other diagnostic and life science companies, as well as contract product development services to strategic partners and alliances; and purchases and resells IVD products, instruments, instrument systems, and various reagents and supplies. The company manufactures and sells approximately 50 diagnostic products to hospitals, clinical testing laboratories, universities, biotechnology and pharmaceutical companies, and research institutions through a network of sales representatives, independent distributors, and private label agreements. Corgenix Medical Corporation has a strategic collaboration with Tulane University, and other industry and academic partners to develop a group of products to detect viruses identified as potential bio-terrorism agents. The company was founded in 1985 and is headquartered in Broomfield, Colorado.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Estimated revenue: $10K – $50K
- Total funding: $1.2M
- Funding stage: M&A
- Last round: Series Unknown (Jul 2010)
- Website: corgenix.com
- Phone: 3034574519
Industries & Categories
Biotechnology, Health Care, Manufacturing, Medical Device
Social Profiles
Canonical: https://fsome.com/organization/corgenix-2509569 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.